Predicted mechanisms of resistance to mTOR inhibitors
Open Access
- 5 September 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 95 (8), 955-960
- https://doi.org/10.1038/sj.bjc.6603353
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- IGF-I mediated survival pathways in normal and malignant cellsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2006
- IRS-1: Auditing the effectiveness of mTOR inhibitorsCancer Cell, 2006
- Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell LymphomaJournal of Clinical Oncology, 2005
- Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth‐inhibitory and VEGF‐suppressive effects of rapamycin in leukemic cellsThe FASEB Journal, 2005
- Cyclin D1 and c-myc Internal Ribosome Entry Site (IRES)-dependent Translation Is Regulated by AKT Activity and Enhanced by Rapamycin through a p38 MAPK- and ERK-dependent PathwayOnline Journal of Public Health Informatics, 2005
- Sustained Activation of the JNK Cascade and Rapamycin-Induced Apoptosis Are Suppressed by p53/p21Cip1Molecular Cell, 2003
- 4E-binding Proteins, the Suppressors of Eukaryotic Initiation Factor 4E, Are Down-regulated in Cells with Acquired or Intrinsic Resistance to RapamycinOnline Journal of Public Health Informatics, 2002
- Correlation between Steady-state ATP Hydrolysis and Vanadate-induced ADP Trapping in Human P-glycoproteinOnline Journal of Public Health Informatics, 2001
- Dominant Mutations Confer Resistance to the Immunosuppressant, Rapamycin, in Variants of a T Cell LymphomaCellular Immunology, 1995
- FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cellsEuropean Journal of Immunology, 1995